CY2526B1 - Compositions and methods for reducing ocular hypertension - Google Patents

Compositions and methods for reducing ocular hypertension

Info

Publication number
CY2526B1
CY2526B1 CY0500033A CY0500033A CY2526B1 CY 2526 B1 CY2526 B1 CY 2526B1 CY 0500033 A CY0500033 A CY 0500033A CY 0500033 A CY0500033 A CY 0500033A CY 2526 B1 CY2526 B1 CY 2526B1
Authority
CY
Cyprus
Prior art keywords
compositions
methods
ocular hypertension
reducing ocular
reducing
Prior art date
Application number
CY0500033A
Other languages
English (en)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2526(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2526B1 publication Critical patent/CY2526B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CY0500033A 1997-03-17 2005-05-26 Compositions and methods for reducing ocular hypertension CY2526B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
CY2526B1 true CY2526B1 (en) 2006-02-08

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0500033A CY2526B1 (en) 1997-03-17 2005-05-26 Compositions and methods for reducing ocular hypertension

Country Status (32)

Country Link
EP (1) EP0969846B2 (enExample)
JP (2) JP4920124B2 (enExample)
KR (1) KR100555818B1 (enExample)
CN (1) CN1236775C (enExample)
AR (2) AR002194A1 (enExample)
AT (1) ATE257385T1 (enExample)
AU (1) AU738781B2 (enExample)
BR (2) BRPI9816218B1 (enExample)
CA (1) CA2280089C (enExample)
CL (1) CL2009001870A1 (enExample)
CO (1) CO4940427A1 (enExample)
CY (1) CY2526B1 (enExample)
CZ (1) CZ299833B6 (enExample)
DE (1) DE69820997T3 (enExample)
DK (1) DK0969846T4 (enExample)
EE (1) EE04091B1 (enExample)
ES (1) ES2214706T5 (enExample)
HU (1) HU228896B1 (enExample)
ID (1) ID22389A (enExample)
IL (1) IL131041A0 (enExample)
MY (1) MY122237A (enExample)
NO (1) NO327713B1 (enExample)
NZ (1) NZ337322A (enExample)
PE (1) PE61899A1 (enExample)
PL (1) PL197509B1 (enExample)
PT (1) PT969846E (enExample)
RU (1) RU2197970C2 (enExample)
SI (1) SI0969846T2 (enExample)
TW (1) TW527187B (enExample)
UA (1) UA63938C2 (enExample)
WO (1) WO1998041208A1 (enExample)
ZA (1) ZA982188B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
ES2331890T3 (es) * 2004-03-18 2010-01-19 R-Tech Ueno, Ltd. Composicion acuosa que comprende un derivado de tiazol.
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
JP5275214B2 (ja) * 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
JPWO2008096804A1 (ja) * 2007-02-07 2010-05-27 テイカ製薬株式会社 ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CN101820917B (zh) * 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
AU2009225931B9 (en) * 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
JP2014510709A (ja) * 2011-04-12 2014-05-01 株式会社アールテック・ウエノ 眼科用水性組成物
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE057140T2 (hu) 2011-12-07 2022-04-28 Allergan Inc Hatásos lipidszállítás humán könny-filmhez sóérzékeny emulziórendszer alkalmazásával
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
BR112021020425A2 (pt) 2019-04-12 2021-12-14 Ecolab Usa Inc Composições de limpeza multiuso concentrada e pronta para uso, e, métodos para limpar uma superfície e de fabricação da composição de limpeza multiuso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
CL2009001870A1 (es) 2010-01-22
DE69820997T3 (de) 2011-10-06
RU2197970C2 (ru) 2003-02-10
NZ337322A (en) 2001-05-25
BR9808016A (pt) 2000-03-08
PE61899A1 (es) 1999-06-30
SI0969846T1 (en) 2004-06-30
SI0969846T2 (sl) 2010-12-31
EE9900410A (et) 2000-04-17
JP2010043110A (ja) 2010-02-25
ID22389A (id) 1999-10-07
EP0969846B2 (en) 2010-08-25
KR100555818B1 (ko) 2006-03-03
ATE257385T1 (de) 2004-01-15
NO327713B1 (no) 2009-09-14
KR20000076330A (ko) 2000-12-26
CO4940427A1 (es) 2000-07-24
WO1998041208A1 (en) 1998-09-24
DK0969846T4 (da) 2010-12-20
JP4920124B2 (ja) 2012-04-18
PL197509B1 (pl) 2008-04-30
CA2280089C (en) 2009-03-03
HU228896B1 (en) 2013-06-28
HK1026841A1 (en) 2000-12-29
BRPI9816218B1 (pt) 2016-04-12
JP2001515502A (ja) 2001-09-18
DE69820997T2 (de) 2004-12-09
TW527187B (en) 2003-04-11
DE69820997D1 (de) 2004-02-12
HUP0002194A2 (hu) 2000-12-28
ES2214706T5 (es) 2011-02-02
HUP0002194A3 (en) 2012-08-28
EP0969846A1 (en) 2000-01-12
CZ299833B6 (cs) 2008-12-10
AU738781B2 (en) 2001-09-27
ZA982188B (en) 1998-09-17
AU7035398A (en) 1998-10-12
MY122237A (en) 2006-04-29
EP0969846B1 (en) 2004-01-07
NO994481D0 (no) 1999-09-16
AR002194A1 (es) 1998-01-07
CN1249687A (zh) 2000-04-05
IL131041A0 (en) 2001-01-28
ES2214706T3 (es) 2004-09-16
NO994481L (no) 1999-09-16
PL335168A1 (en) 2000-04-10
PT969846E (pt) 2004-05-31
CN1236775C (zh) 2006-01-18
AR011192A1 (es) 2000-08-02
CA2280089A1 (en) 1998-09-24
UA63938C2 (uk) 2004-02-16
DK0969846T3 (da) 2004-04-13
EE04091B1 (et) 2003-08-15
CZ325799A3 (cs) 2000-01-12

Similar Documents

Publication Publication Date Title
IL131041A0 (en) Compositions and methods for reducing ocular hypertension
AU3767097A (en) Shampoo compositions and method
ZA958028B (en) Compositions and methods for treatig mast-cell mediated conditions
AU8693098A (en) Compositions and methods for treating diabetes
AU9214398A (en) Compositions and methods for treating water
ZA989400B (en) Method and composition
IL133784A0 (en) Dolastatin 15 derivatives
AU2349399A (en) R-lansoprazole compositions and methods
ZA989398B (en) Method and composition (l)
EP1056457A4 (en) S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
AU2664797A (en) Wnt receptor compositions and methods
GB9624501D0 (en) Insecticial compositions and method
EP1073333A4 (en) S-RABEPRAZOL COMPOSITIONS AND METHODS
AUPO982097A0 (en) Methods and compositions for use therein
AU9393798A (en) Genetic compositions and methods
AU5546298A (en) Methods and compositions for preventing autoimmune disease
EP1073332A4 (en) R-RABEPRAZOL COMPOSITIONS AND METHODS
AU3900499A (en) (+)-hydroxyrisperidone compositions and methods
AU7287798A (en) Compositions and methods for bioremediation
AU7799898A (en) Compositions and methods for treating glaucoma
AU9105498A (en) Novel compositions and methods for controlling nematodes
AU9474898A (en) Methods and compositions for diagnosing and treating malaria
GB9719842D0 (en) Ophthalmic compositions for treating ocular hypertension
GB9717153D0 (en) Eyedrop composition
GB9720017D0 (en) Composition and method